Tasimelteon - Vanda Pharmaceuticals

Drug Profile

Tasimelteon - Vanda Pharmaceuticals

Alternative Names: BMS-214778; HETLIOZ; VEC-162

Latest Information Update: 05 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Vanda Pharmaceuticals
  • Class Amides; Antidepressants; Benzofurans; Cyclopropanes; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Circadian rhythm sleep disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Circadian rhythm sleep disorders
  • Discontinued Major depressive disorder

Most Recent Events

  • 01 Aug 2018 Vanda Pharmaceuticals announces intention to submit sNDA to the US FDA for Circadian rhythm sleep disorders (Jet lag disorder), by the end of 2018
  • 24 Jun 2018 Biomarkers information updated
  • 23 May 2018 Vanda Pharmaceuticals terminates a phase II trial in Circadian rhythm sleep disorders (Jet lag type insomnia) in United Kingdom and USA (NCT03291041) (EudraCT2016-002213-21)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top